Sandoz Canada
www.sandoz.ca
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sandoz Canada
Ninth Canadian Jurisdiction Implements Biosimilar Switching Policy
Newfoundland and Labrador has become the ninth jurisdiction in Canada to implement a biosimilar switching policy for patients enrolled on its public health program.
Jamp To Offer Canadian Sitagliptin, Sandoz Bags Fixed-Dose Combo
An important mono- and adjunct therapy for diabetes patients now has generic competition in Canada, where an estimated 10% of the population are said to have been diagnosed with type 1 or type 2 diabetes.
Valeo Expects Full Enoxaparin Biosimilar Coverage By Year End
Canadian firm Valeo Pharma revealed the extent of coverage for its Lovenox biosimilars, months after launching the low molecular weight heparin in-licensed from Shenzhen Techdow Pharmaceutical.
Court Ruling Gives Sandoz Canada First Generic Pirfenidone
A favorable court ruling has allowed Sandoz Canada to launch the first generic version of Roche’s Esbriet to treat idiopathic pulmonary fibrosis.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice